Boehringer ends development of Alzheimer’s candidate
Boehringer Ingelheim is ending development of BI 409306 in Alzheimer’s disease on disappointing mid-stage trial data.
Read More
Tag: BI 409306
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
